<DOC>
	<DOCNO>NCT00390026</DOCNO>
	<brief_summary>The object study compare treatment effect bevacizumab ( Avastin ) , antibody target vascular endothelial growth factor , verteporfin photodynamic therapy ( PDT ) patient neovascular age-related macular degeneration , lead cause vision severe loss Western world .</brief_summary>
	<brief_title>The Avastin v Visudyne Neovascular AMD Study</brief_title>
	<detailed_description>Neovascular age-related macular degeneration ( AMD ) cause ingrowth pathological vessel macula . Experimental study demonstrate vascular endothelial growth factor ( VEGF ) centrally involved process . Current treatment option limit photodynamic therapy ( PDT ) photosensitize agent combination laser use occlude pathologic vessel . Anti-VEGF agent recently become available make potentially attractive treatment alternative neovascular AMD . We compare effect intravitreally administer bevacizumab conventional PDT prospective , randomize control trial include 100 patient ( 50 patient receive either treatment regimen ) . Non-treated patient receive either sham-injection sham-PDT . The primary endpoint study amount patient lose less 15 letter ETDRS visual acuity chart . The study go 2 year interim report 1 year .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>patient subfoveal neovascular AMD either classic/predominantly classic small occult lesion visual acuity &gt; =0.1 patient subfoveal neovascular AMD minimally classic lesion large occult lesion subfoveal hemorrhage ( &gt; 1DA ) fibrosis patient previously treat neovascular AMD study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Neovascular age-related macular degeneration</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Photodynamic therapy</keyword>
</DOC>